Germany's Merck KGaA is buying U.K. gene-silencing biotech for $1.3 billion
The all-cash deal adds divesiran, an experimental rare-disease drug ready for late-stage trials, to Merck's pipeline
We haven't written up this one. Quartz has the full story — the link below goes straight to it.